PCSK9 significantly conferred prediction of both hypercholesterolemia and combined hyperlipidemia at levels of 235 ng/ml; apoC3 levels for hypertriglyceridemia, hypercholesterolemia and combined hyperlipidemia were 80.0, 71.5, and 86.4 μg/ml, respectively; and sdLDL-C for hypertriglyceridemia, hypercholesterolemia, combined hyperlipidemia and hypo HDL cholesterolemia were 3.5, 2.5, 4.5, and 2.5 mg/dl, respectively (all p < 0.001). This evidence concerns the gene PCSK9 and hyperlipidemia.